K
Keiko Minashi
Researcher at Gunma University
Publications - 115
Citations - 5734
Keiko Minashi is an academic researcher from Gunma University. The author has contributed to research in topics: Chemoradiotherapy & Cancer. The author has an hindex of 28, co-authored 99 publications receiving 4164 citations.
Papers
More filters
Journal ArticleDOI
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang,Narikazu Boku,Taroh Satoh,Min Hee Ryu,Yee Chao,Ken Kato,Hyun Cheol Chung,Jen-Shi Chen,Kei Muro,Won Ki Kang,Kun-Huei Yeh,Takaki Yoshikawa,Sang Cheul Oh,Li Yuan Bai,Takao Tamura,Keun Wook Lee,Yasuo Hamamoto,Jong Gwang Kim,Keisho Chin,Do Youn Oh,Keiko Minashi,Jae Yong Cho,Masahiro Tsuda,Li-Tzong Chen,Li-Tzong Chen +24 more
TL;DR: In this phase 3 study, the survival benefits indicate that nivolumab might be a new treatment option for heavily pretreated patients with advanced gastric or gastro-oesophageal junction cancer.
Journal ArticleDOI
Early Detection of Superficial Squamous Cell Carcinoma in the Head and Neck Region and Esophagus by Narrow Band Imaging: A Multicenter Randomized Controlled Trial
Manabu Muto,Keiko Minashi,Tomonori Yano,Yutaka Saito,Ichiro Oda,Satoru Nonaka,Tai Omori,Hitoshi Sugiura,Kenichi Goda,Mitsuru Kaise,Haruhiro Inoue,Hideki Ishikawa,Atsushi Ochiai,Tadakazu Shimoda,Hidenobu Watanabe,Hisao Tajiri,Daizo Saito +16 more
TL;DR: NBI could be the standard examination for the early detection of superficial cancer in the H&N region and the esophagus between conventional white light imaging and NBI in high-risk patients.
Journal ArticleDOI
Development and evaluation of FSSG: frequency scale for the symptoms of GERD
Motoyasu Kusano,Yasuyuki Shimoyama,Sayaka Sugimoto,Osamu Kawamura,Masaki Maeda,Keiko Minashi,Shiko Kuribayashi,Tatsuya Higuchi,Hiroaki Zai,Kyoko Ino,Tsutomu Horikoshi,Sugiyama T,Munetoshi Toki,Tsuneo Ohwada,Masatomo Mori +14 more
TL;DR: The score obtained using the questionnaire correlated well with the extent of endoscopic improvement in patients with mild or severe GERD, and was useful for the objective evaluation of symptoms in GERD patients.
Journal ArticleDOI
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo,Yasuo Hamamoto,Ken Kato,Takashi Ura,Takashi Kojima,Takahiro Tsushima,Shuichi Hironaka,Hiroki Hara,Taroh Satoh,Satoru Iwasa,Kei Muro,Hirofumi Yasui,Keiko Minashi,Kensei Yamaguchi,Atsushi Ohtsu,Yuichiro Doki,Yuko Kitagawa +16 more
TL;DR: Nivolumab showed promising activity with a manageable safety profile and could offer a potential new treatment approach for patients with treatment-refractory advanced squamous-cell carcinoma.
Journal ArticleDOI
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Ken Kato,Kei Muro,Keiko Minashi,Atsushi Ohtsu,Satoshi Ishikura,Narikazu Boku,Hiroya Takiuchi,Yoshito Komatsu,Yoshinori Miyata,Haruhiko Fukuda +9 more
TL;DR: CRT is effective for Stage II-III ESCC with manageable acute toxicities and can provide a nonsurgical treatment option, however, further improvement is required for reduction in late toxicity.